4.7 Article

Serum glial fibrillary acidic protein is sensitive to acute but not chronic tissue damage in cerebral small vessel disease

Related references

Note: Only part of the references are listed.
Review Clinical Neurology

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

Ahmed Abdelhak et al.

Summary: Blood-derived biomarkers, such as glial fibrillary acidic protein (GFAP), hold promise in the diagnosis and prognosis of neurological diseases. However, there are limitations that hinder the widespread clinical use of GFAP as a biomarker.

NATURE REVIEWS NEUROLOGY (2022)

Article Psychiatry

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease

Pratishtha Chatterjee et al.

Summary: The study found that plasma GFAP levels are elevated in cognitively normal older adults at risk of AD, indicating that astrocytic damage or activation may start from the pre-symptomatic stage of the disease and is associated with brain Aβ load. The potential of plasma GFAP to contribute to a diagnostic blood biomarker panel, along with plasma Aβ 1-42/Aβ 1-40 ratios, for cognitively normal older adults at risk of AD was highlighted by the observations from the present study.

TRANSLATIONAL PSYCHIATRY (2021)

Article Clinical Neurology

Serum GFAP for stroke diagnosis in regions with limited access to brain imaging (BE FAST India)

Love-Preet Kalra et al.

Summary: The study showed that GFAP testing system is effective in ruling out intracranial hemorrhage in Indian stroke patients, improving diagnostic accuracy. In settings without immediate access to brain imaging, it allows for implementing secondary prevention measures in suspected ischemic stroke patients as soon as possible.

EUROPEAN STROKE JOURNAL (2021)

Article Immunology

Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL

Chih-Hao Chen et al.

JOURNAL OF NEUROINFLAMMATION (2020)

Article Multidisciplinary Sciences

Early renal dysfunction and fibroblast growth factor-23 in patients with small vessel disease-related stroke

Simon Fandler-Hoefler et al.

SCIENTIFIC REPORTS (2019)

Article Toxicology

Glial fibrillary acidic protein as a prognostic marker of acute ischemic stroke

G. Liu et al.

HUMAN & EXPERIMENTAL TOXICOLOGY (2018)

Article Clinical Neurology

Serum neurofilament light is sensitive to active cerebral small vessel disease

Thomas Gattringer et al.

NEUROLOGY (2017)

Article Endocrinology & Metabolism

Progression of MRI markers in cerebral small vessel disease: Sample size considerations for clinical trials

Philip Benjamin et al.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2016)

Article Multidisciplinary Sciences

Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients

Changhong Ren et al.

SCIENTIFIC REPORTS (2016)

Article Geriatrics & Gerontology

Magnetization transfer ratio relates to cognitive impairment in normal elderly

Stephan Seiler et al.

FRONTIERS IN AGING NEUROSCIENCE (2014)

Review Clinical Neurology

Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging

Joanna M. Wardlaw et al.

LANCET NEUROLOGY (2013)

Review Neurosciences

GFAP in health and disease

J. Middeldorp et al.

PROGRESS IN NEUROBIOLOGY (2011)

Review Geriatrics & Gerontology

Blood-brain barrier: Ageing and microvascular disease-systematic review and meta-analysis

Andrew J. Farrall et al.

NEUROBIOLOGY OF AGING (2009)

Article Clinical Neurology

Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke

C Foerch et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)